



Business Results



Teva continued to deliver solid performance this quarter, with revenues coming in at \$3.9 billion, up 4% vs. Q2 2022 in local currency terms and non-GAAP gross margin up 3.1 percentage points vs. Q1 2023. Our growth drivers continue to provide confidence in our Pivot to Growth strategy, highlighted by strong growth from AUSTEDO®, a successful new innovative product launch of UZEDY™ and growth of our generics business in local currency terms. With this solid performance, we are slightly increasing the midpoint of our revenue guidance for the year and reaffirming all other guidance items.

As we remain determined to execute on our growth strategy, we are continuing to focus on our late-stage innovative pipeline delivery and early-stage pipeline development, both organically and through collaborations. ■■

Richard Francis
President & Chief Executive Officer

Q2 2023 Financial Results

Q2 results

2023 Guidance
(Revised)



Revenues
\$3.9 billion

\$15.0 - \$15.4 billion




EPS*
\$0.56

\$2.25 - \$2.55
*Non-GAAP EPS



Free Cash Flow
\$632 million

\$1.7 - \$2.1 billion



Highlights


Solid Q2 performance driven by growth drivers
AUSTEDO® (deutetrabenazine) - increased 51% vs. Q2 2022, mainly driven by growth in volume and the launch of AUSTEDO XR once daily formulation in May 2023.
UZEDY™ (risperidone) - early signals post May 2023 launch reflect optimism
AJOVY® (fremanezumab-vfrm) - continued growth momentum

Tangible progress along Pivot to Growth strategy
Biosimilars - expansion of Alvotech partnership
Olanzapine LAI & Anti-TL1A - on track for next development milestones
Teva API - executing on standalone plan

Stable Generics Business
 Europe and International Markets generics revenues in Q2 increased 2% and 13% respectively, in local currency terms, compared to the same quarter last year. Continued focus on high value complex products and service level improvement

Updating 2023 guidance
 Full year 2023 revenues outlook increased to \$15.0-\$15.4 from \$14.8-\$15.4 billion

Q2 2023 Solid Performance % In local currency, compared to Q2 2022



Executing on all Four Pillars of Pivot to Growth Strategy



Deliver on growth engines

- AUSTEDO to reach \$1.2 billion in 2023; Reaffirming Goal to Achieve \$2.5B by 2027
- UZEDY launch and uptake



Step up innovation

- Accelerated development of Innovative late-stage assets
- New leadership in innovative R&D and business development



Sustain generics powerhouse

- Focus on high-value generics R&D projects
- Reallocation of resources
- Optimized manufacturing network



Focus our business

- Teva API (TAPI) standalone unit
- Capital reallocation towards growth engines and innovation

Our Recent ESG Progress

Target Updates



ACCESS TO MEDICINES

7th program launched in Chile (of 8 - 2025 target)

31 cumulative regulatory submissions* (43% of 2025 target)



ENVIRONMENTAL IMPACT

24% reduction in scope 1 and 2 greenhouse gas emissions (52% of 2030 target)



ETHICS AND COMPLIANCE

99.6% of employees trained on compliance policies (achieved 2023 target ahead of schedule)

Additional Highlights

7 states added to US mental health program (10 total)

100% renewable electricity contract signed for all Teva Israel sites (~15% of Teva's total electricity use)

16.9M doses of medicines donated as part of Access programs (including ~400K SLB relevant)

AMR certification program initiated in partnership with AMR Industry Alliance (1 of 6 pilot companies)

Driving Long-Term Sustainability and Value Creation

*in low- and middle-income countries on WHO's Essential Medicines List across six key therapeutic areas (2022 – 2025)

Cautionary Note Regarding Forward-Looking Statements

This Infographic contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our innovative medicines, including AUSTEDO, AJOVY and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; our ability to successfully launch and execute our new strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; our ability to attract, hire, integrate and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for intellectual property right infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption, sanctions and trade control laws; environmental risks; and the impact of ESG issues;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the ongoing conflict between Russia and Ukraine; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and other factors discussed in this Infographic, in our Quarterly Report on Form 10-Q for the second quarter of 2023 and in our Annual Report on Form 10-K for the year ended December 31, 2022, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.